A two-year follow-up clinical trial found that a new personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated strong safety and improved overall survival in patients, according to findings published in Blood.
A study by a scientific team from the University of Vienna and the MedUni Vienna, recently published in Cellular & Molecular Immunology, shows that the enzyme phosphoglycerate dehydrogenase (PHGDH) acts as a metabolic checkpoint in the function of tumo…
Researchers at the Technion’s Ruth and Bruce Rappaport Faculty of Medicine and the Rappaport Family Institute for Research in the Medical Sciences have discovered a subset of blood cells that predict the success of immunotherapy treatment. These findin…
Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood has published the preclinical…
In an early-phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer. The findings are published in Cancer.
